Stargeting TNF-alpha to elucidate and ameliorate neuroinflammation in neurodegenerative diseases

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 3, 2011, Pages 391-403

  Frankola, Kathryn A ^a   Greig, Nigel H ^a   Luo, Weiming ^a   Tweedie, David ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Chemokine; Cytokine; Dementia; Japanese encephalitis; Neuro degeneration; Neuro inflammation; Parkinson's disease; Revlimid; Thalidomide; Tumor necrosis factor alpha

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMYLOID BETA PROTEIN; CASPASE INHIBITOR; COMPLEMENT COMPONENT C5A RECEPTOR; DEXAMETHASONE; ETANERCEPT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LENALIDOMIDE; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ASTHMA; BONE MARROW DISEASE; BRAIN FUNCTION; CELL FUNCTION; CELL VIABILITY; CROHN DISEASE; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DRUG TARGETING; EPILEPSY; GENE EXPRESSION; HIV ASSOCIATED DEMENTIA; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; JAPANESE ENCEPHALITIS; LIVER CIRRHOSIS; MICROGLIA; MULTIPLE MYELOMA; NEOPLASM; NERVOUS SYSTEM INFLAMMATION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PERIPHERAL NERVOUS SYSTEM; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; RHEUMATOID ARTHRITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SYNAPSE; TERATOGENESIS; TRAUMATIC BRAIN INJURY; CELL SURVIVAL; DEGENERATIVE DISEASE; METABOLISM; MOLECULARLY TARGETED THERAPY; NEURITIS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; UPREGULATION;

ALZHEIMER DISEASE; CELL SURVIVAL; HUMANS; MOLECULAR TARGETED THERAPY; NEURITIS; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 79951701971     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152711794653751     Document Type: Article

References (185)

1. Frank-Cannon, T.C.; Alto, L.T.; McAlpine, F.E.; Tansey, M.G. Does neuroinflammation fan the flame in neurodegenerative diseases? Mol. Neurodegen., 2009, 16, 47.
2. Tansey, M.G.; Goldberg, M.S. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis., 2010, 37, 510-518.
3. Alzheimer's Assocation. Alzheimer's Disease Facts and Figures. Alzheimers Dement., 2009, 5, 234-270.
4. Yan, Y.P.; Lang, B.T.; Vemuganti, R.; Dempsey, R.J. Galectin-3 mediates post-ischemic tissue remodeling. Brain Res., 2009, 1288, 116-124.
5. Lecca, D.; Trincavelli, M.L.; Gelosa, P.; Sironi, L.; Ciana, P.; Fumagalli, M.; Villa, G; Verderio, C.; Grumelli, C.; Guerrini, U; Tremoli, E; Rosa, P; Cuboni, S; Martini, C.; Buffo, A.; Cimino, M.; Abbraccio, M.P. The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair. PLoS One, 2008, 3(10), e3579.
6. Bessis, A.; Béchade, C.; Bernard, D.; Roumier, A. Microglial control of neuronal death and synaptic properties. Glia, 2007, 55, 233-238.
7. Streit, W.J. Microglia and macrophages in the developing CNS. Neurotoxicology, 2001, 22, 619-624.
8. Liu, B.; Hong, J-S. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J. Pharmacol. Exp. Ther., 2003, 304, 1-7.
9. McGeer, P.L.; Itagaki, S.; Boyes, B.E.; McGeer, E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology, 1988, 38, 1285-1291.
10. Streit, W.J.; Xue, Q-J. Life and death of microglia. J. Neuroimmune Pharmacol., 2009, 4, 371-379.
11. von Bernhardi, R.; Tichauer, J.E.; Eugenín, J. Aging-dependent changes of microglial cells and their relevance for neurodegenerative disorders. J. Neurochem., 2010, 112, 1099-1114.
12. Das, S.; Potter, H. Expression of the Alzheimer amyloid-promoting factor antichymotrypsin is induced in human astrocytes by IL-1. Neuron, 1995, 4, 447-456.
13. Griffin, W.S.; Stanley, L.C.; Ling, C.; White, L.; MacLeod, V.; Perrot, L.J.; White, C.L. 3rd; Araoz, C. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. USA, 1989, 86, 7611-7615.
14. Rogers, J.T.; Leiter, L.M.; McPhee, J.; Cahill, C.M.; Zhan, S.S.; Potter, H.; Nilsson, L.N. Translation of the alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5'-untranslated region sequences. J. Biol. Chem., 1999, 274, 6421-6431.
15. Rogers, J.T.; Randall, J.D.; Cahill, C.M.; Eder, P.S.; Huang, X.; Gunshin, H.; Leiter, L.; McPhee, J.; Sarang, S.S.; Utsuki, T.; Greig, N.H.; Lahiri, D.K.; Tanzi, R.E.; Bush, A.I.; Giordano, T.; Gullans, S.R. An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J. Biol. Chem., 2002, 277, 45518-45528.
16. Lahiri, D.K.; Chen, D., Vivien, D.; Ge, Y.W.; Greig, N.H.; Rogers, J.T. Role of cytokines in the gene expression of amyloid ß-protein precursor: identification of a 5'-UTR-Binding nuclear factor and its implications in Alzheimer's disease. J. Alzheimers Dis., 2003a, 5, 81-90.
17. Selkoe, D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev., 2001, 81, 741-766.
18. Avramovich, Y.; Amit, T.; Youdim, M.B.H. Non-steroidal anti-inflammatory drugs stimulate secretion of non-amyloidogenic precursor protein. J. Biol. Chem., 2002, 277, 31466-31473.
19. Lahiri, D.K.; Farlow, M.R.; Sambamurti, K.; Grieg, N.H.; Giacobini, E.; Schneider, L.S. A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr. Drug Targets, 2003, 4, 97-112.
20. Funato, H.; Yoshimura, M.; Yamazaki, T.; Saido, T.C.; Ito, Y.; Yokofujita, J.; Okeda, R.; Ihara, Y. Astrocytes containing amyloid beta-protein (Abeta)-positive granules are associated with Abeta40-positive diffuse plaques in the aged human brain. Am. J. Pathol., 1998, 152, 983-992.
21. Akiyama, H.; Barger, S.; Barnum, S.; Bradt, B.; Bauer, J.; Cole, G.M.; Cooper, N.R.; Eikelenboom, P.; Emmerling, M.; Fiebich, B.L.; Finch, C.E.; Frautschy, S.; Griffen, W.S.; Hampel, H.; Hull, M.; Landreth, G.; Lue, L.; Mrak, R.; Mackenzie, I.R.; McGeer, P.L.; O'Banion, M.K.; Pachter, J.; Pasinetti, G.; Plata-Salaman, C.; Rogers, J.; Rydel, R.; Shen, Y.; Streit, W.; Strohmeyer, R.; Tooyoma, I.; Van Muiswinkel, F.L.; Veerhuis, R.; Walker, D.; Webster, S.; Wegryzniak, B.; Wenek, G.; Wyass-Coray, T. Inflammation and Alzheimer's disease. Neurobiol. Aging, 2002, 21, 383-421.
22. Bamberger, M.E.; Harris, M.E.; McDonald, D.R.; Husemann, J.; Landreth, G.E. A cell surface receptor complex for fibrillar betaamyloid mediates microglial activation. J. Neurosci., 2003, 23, 2665-2674.
23. Combs, C.K.; Karlo, J.C.; Kao, S.C.; Landreth, G.E. Beta-amyloid stimulation of microglia and monocytes results in TNF alphadependent expression of inducible nitric oxide synthase and neuronal apoptosis. J. Neurosci., 2001, 21, 1179-1188.
24. Liao, Y.F.; Wang, B.J.; Cheng, H.T.; Kuo, L.H.; Wolfe, M.S. Tumor necrosis factor-alpha, interleukin-1beta, and interferongamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J. Biol. Chem., 2004, 279, 49523-49532.
25. Alkam, T.; Nitta, A.; Mizoguchi, H.; Saito, K.; Seshima, M.; Itoh, A.; Yamada, K.; Nabeshima, T. Restraining tumor necrosis factoralpha by thalidomide prevents the amyloid beta-induced impairment of recognition memory in mice. Behav. Brain Res., 2008, 189, 100-106.
26. Zhang, C.; Browne, A.; Kim, D.Y.; Tanzi, R.E. Familial Alzheimer's disease mutations in presenilin 1 do not alter levels of the secreted amyloid-beta protein precursor generated by beta-secretase cleavage. Curr. Alzheimer Res., 2010, 7, 21-26.
27. Perry, R.T.; Collins, J.S.; Wiener, H.; Acton, R.; Go, R.C. The role of TNF and its receptors in Alzheimer's disease. Neurobiol. Aging, 2001, 22, 873-883.
28. Gao, H-M.; Liu, B.; Zhang, W.; Hong, J-S. Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol. Sci., 2003, 24, 395-401.
29. Aisen, P.S. Anti-inflammatory therapy for Alzheimer's disease: Implications of the prednisone trial. Acta Neurol. Scand., 2000, 176, 85-89.
30. Hirsch, E.C.; Hunot, S.; Damier, P.; Faucheux, B. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann. Neurol., 1998, 44, S115-S120.
31. Stewart, W.F.; Kawas, C.; Corrada, M.; Metter, E.J. Risk of Alzheimer's disease and duration of NSAID use. Neurology, 1997, 48, 626-632.
32. Oddo, S.; Caccamo, A.; Shepherd, J.D.; Murphy, M.P.; Golde, T.E.; Kayed, R.; Metherate, R.; Mattson, M.P.; Akbari, Y.; LaFerla, F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron, 2003, 39, 409-421.
33. Oddo, S.; Caccamo, A.; Kitazawa, M.; Tseng, B.P.; LaFerla, F.M. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol. Aging, 2003, 8, 1063-1070.
34. Janelsins, M.C.; Mastrangelo, M.A.; Oddo, S.; La Ferla, F.M.; Federoff, H.J.; Bowers, W.J. Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J. Neuroinflammation, 2005, 2, 23.
35. Janelsins, M.C.; Mastrangelo, M.A.; Park, K.M.; Sudol, K.L.; Narrow, W.C.; Oddo, S.; LaFerla, F.M.; Callahan, L.M.; Federoff, H.J.; Bowers, W.J. Chronic neuron-specific tumor necrosis factoralpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Am. J. Pathol., 2008, 173, 1768-1782.
36. McAlpine, F.E.; Lee, J.K.; Harms, A.S.; Ruhn, K.A.; Blurton-Jones, M.; Hong, J.; Das, P.; Golde, T.E.; LaFerla, F.M.; Oddo, S.; Blesch, A.; Tansey, M.G. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloidassociated neuropathology. Neurobiol. Dis., 2009, 34, 163-177.
37. Fonseca, M.I.; Ager, R.R.; Chu, S.H.; Yazan, O.; Sanderson, S.D.; LaFerla, F.M.; Taylor, S.M.; Woodruff, T.M.; Tenner, A.J. Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J. Immunol., 2009, 183(2), 1375-1383.
38. Tobinick, E.; Gross, H.; Weinberger, A.; Cohen, H. TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. Med Gen Med, 2006, 8, 25.
39. Tobinick, E.L.; Gross, H. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J. Neuroinflammation, 2008, 5, 2.
40. Tobinick, E.L.; Gross, H. Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease. BMC Neurol., 2008, 8, 27.
41. Ferger, B.; Leng, A.; Mura, A.; Hengerer, B.; Feldon, J. Genetic ablation of tumor necrosis factor-alpha (TNF-α) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. J. Neurochem., 2004, 89, 822-833.
42. Westerlund, M.; Hoffer, B.; Olson, L. Parkinson's disease: exit toxins, enter genetics. Prog. Neurobiol., 2010, 90, 146-156.
43. Varani, K.; Vincenzi, F.; Tosi, A.; Gessi, S.; Casetta, I.; Granieri, G.; Fazio, P.; Leung, E.; MacLennan, S.; Granieri, E.; Borea, P.A. A2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson's disease. FASEB J., 2010, 24, 587-598.
44. Mogi, M.; Harada, M.; Riederer, P.; Narabayashi, H.; Fujita, K.; Nagatsu, T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett., 1994, 165, 208-210.
45. Nagatsu, T.; Mogi, M.; Ichinose, H.; Togari, A. Changes in cytokines and neurotrophins in Parkinson's disease. J. Neural Transm., 2000, 60, 277-290.
46. Lawson, L.J.; Perry, V.H.; Dri, P.; Gordon, S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience, 1990, 39, 151-170.
47. Boka, G.; Anglade, P.; Wallach, D.; Javoy-Agid, F.; Agid, Y.; Hirsch, E.C. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci. Lett., 1994, 172, 151-154.
48. Mogi, M.; Togari, A.; Kondo, T.; Mizuno, T.; Komure, O.; Kuno, S.; Ichinose, H.; Nagatsu, T. Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from Parkinsonian brain. J. Neural Transm., 2000, 107, 335-341.
49. Westerlund, M.; Hoffer, B.; Olson, L. Parkinson's disease: exit toxins, enter genetics. Prog. Neurobiol., 2010, 90, 146-156.
50. Langston, J.W.; Ballard, P.; Tetrud, J.W.; Irwin, I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science, 1983, 219, 979-980.
51. Nicklas, W.J.; Youngster, S.K.; Kindt, M.V.; Heikkila, R.E. MPTP, MPP+ and mitochondrial function. Life Sci., 1987, 40, 721-729.
52. Kovacic, P.; Edwards, W.D.; Ming, G. Theoretical studies on mechanism of MPTP action: ET interference by MPP+ (1-methyl-4-phenylpyridinium) with mitochondrial respiration vs oxidative stress. Free Radic. Res. Commun., 1991, 14, 25-32.
53. Przedborski, S.; Kostic, V.; Jackson-Lewis, V.; Naini, A.B.; Simonetti, S.; Fahn, S.; Carlson, E.; Epstein, C.J.; Cadet, J.L. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J. Neurosci., 1992, 12, 1658-1667.
54. Kang, D.; Miyako, K.; Kuribayashi, F.; Hasegawa, E.; Mitsumoto, A.; Nagano, T.; Takeshige, K. Changes of energy metabolism induced by 1-methyl-4-phenylpyridinium (MPP+)-related compounds in rat pheochromocytoma PC12 cells. Arch. Biochem. Biophys., 1997, 337, 75-80.
55. Chan, P.; DeLanney, L.E.; Irwin, I.; Langston, J.W.; Di Monte, D. Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain. J. Neurochem., 1991, 57, 348-351.
56. Denton, T.; Howard, B.D. A dopaminergic cell line variant resistant to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Neurochem., 1987, 49, 622-630.
57. Marini, A.M.; Nowak, T.S. Jr. Metabolic effects of 1-methyl-4-phenylpyridinium (MPP(+)) in primary neuron cultures. J. Neurosci. Res., 2000, 62, 814-820.
58. McGeer, P.L.; Schwab, C.; Parent, A.; Doudet, D. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann. Neurol., 2003, 54, 599-604.
59. Lahiri, D.K.; Maloney, B.; Zawia, N.H. The LEARn model: an epigenetic explanation for idiopathic neurobiological diseases. Mol. Psychiatry, 2009, 14, 992-1003.
60. Jang, H.; Boltz, D.A.; Webster, R.G.; Smeyne, R.J. Viral parkinsonism. Biochim. Biophys. Acta, 2009, 1792, 714-721.
61. Calne, D.B.; Lees, A.J. Late progression of post-encephalitic Parkinson's syndrome. Can. J. Neurol. Sci., 1988, 15, 135-138.
62. Mawdsley, C.; Ferguson, F.R. Neurological disease in boxers. Lancet, 1963, 2, 795-801.
63. Bostantjopoulou, S.; Katsarou, Z.; Michael, M.; Petridis, A. Reversible parkinsonism due to chronic bilateral subdural hematomas. J. Clin. Neurosci., 2009, 16, 458-460.
64. Rugbjerg, K.; Ritz, B.; Korbo, L.; Martinussen, N.; Olsen, J.H. Risk of Parkinson's disease after hospital contact for head injury: population based case-control study. BMJ, 2008, 337, a2494.
65. Cicchetti, F.; Drouin-Ouellet, J.; Gross, R.E. Environmental toxins and Parkinson's disease: what have we learned from pesticideinduced animal models? Trends Pharmacol. Sci., 2009, 30, 475-483.
66. Tweedie, D.; Sambamurti, K.; Greig, N.H. TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Curr. Alzheimer Res., 2007, 4, 378-385.
67. Ciesielska, A.; Joinec, I.; Przybylkowski, A.; Gromadzka, G.; Kurkowska-Jastrzebska, I.; Czlonkowska, A.; Czlonkowska, A. Dynamics of expression of the mRNA for cytokines and inducible nitric synthase in a murine model of the Parkinson's disease. Acta. Neurobiol. Exp. (Wars.), 2003, 63, 117-126.
68. Hebert, G.; Arsaut, J.; Dantzer, R.; Demontes-Mainard, J. Timecourse of the expression of inflammatory cytokines and matrix metalloproteinases in the striatum and mesencephalon of mice injected with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a dopaminergic neurotoxin. Neurosci. Lett., 2003, 349, 191-195.
69. Mladenovic, A.; Perovic, M.; Raicevic, N.; Kanazir, S.; Rakic, L.; Ruzdijic, S. 6-Hydroxydopamine increases the level of TNFα and bax mRNA in the striatum and induces apoptosis of dopaminergic neurons in hemiparkinsonian rats. Brain Res., 2004, 996, 237-345.
70. De Lella Ezcurra, A.L.; Chertoff, M.; Ferrari, C.; Graciarena, M.; Pitossi, F. Chronic expression of low levels of tumor necrosis factor-alpha in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation. Neurobiol. Dis., 2010, 37, 630-640.
71. Boireau, A.; Bordier, F.; Dubedat, P.; Peny, C.; Imperato, A. Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice. Neurosci. Lett., 1997, 234, 123-126.
72. Sriram, K.; Matheson, J.M.; Benkovic, S.A.; Miller, D.B.; Luster, M.I.; O'Callaghan, J.P. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J., 2002, 16, 1474-1476.
73. Rousselet, E.; Callebert, J.; Parain, K.; Joubert, C.; Hunot, S.; Hartmann, A.; Jacque, C.; Perez-Diaz, F.; Cohen-Salmon, C.; Launay, J.M.; Hirsch, E.C. Role of TNF-α receptors in mice intoxicated with the Parkinsonian toxin MPTP. Exper. Neurol., 2002, 177, 183-192.
74. Leng, A.; Mura, A.; Feldon, J.; Ferger, B. Tumor necrosis factoralpha receptor ablation in a chronic MPTP mouse model of Parkinson's disease. Neurosci. Lett., 2005, 375, 107-111.
75. Togo, T.; Iseki, E.; Marui, W.; Akiyama, H.; Ueda, K.; Kosaka, K. Glial involvement in the degeneration process of Lewy body bearing neurons and the degradation process of Lewy bodies in brains of dementia with Lewy bodies. J. Neurol. Sci., 2001, 184, 71-75.
76. Imamura, K.; Hishikawa, N.; Ono, K.; Suzuki, H.; Sawada, M.; Nagatsu, T.; Yoshida, M.; Hashizume, Y. Cytokine production of activated microglia and decrease in neurotrophic factors of neurons in the hippocampus of Lewy body disease brains. Acta Neuropathol., 2005, 109, 141-150.
77. Zhang, W.; Wang, T.; Pei, Z.; Miller, D.S.; Wu, X.; Block, M.L.; Wilson, B.; Zhang, W.; Zhou, Y.; Hong, J.S.; Zhang, J. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J., 2005, 19, 533-542.
78. Su, X.; Maguire-Zeiss, K.A.; Giuliano, R.; Prifti, L.; Venkatesh, K.; Federoff, H.J. Synuclein activates microglia in a model of Parkinson's disease. Neurobiol. Aging, 2008, 29, 1690-1701.
79. Katsuse, O.; Iseki, E.; Kosaka, K. Immunohistochemical study of the expression of cytokines and nitric oxide synthases in brains of patients with dementia with Lewy bodies. Neuropathology, 2003, 23, 9-15.
80. Gurney, M.E.; Pu, H.; Chiu, A.Y.; Dal Canto, M.C.; Polchow, C.Y.; Alexander, D.D.; Caliendo, J.; Hentati, A.; Kwon, Y.W.; Deng, H.X. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science, 1994, 264, 1172-1175.
81. Ferri, A.; Nencini, M.; Cozzolino, M.; Carrara, P.; Moreno, S.; Carrì, M.T. Inflammatory cytokines increase mitochondrial damage in motoneuronal cells expressing mutant SOD1. Neurobiol. Dis., 2008, 32, 454-460.
82. Stommel, E.W.; van Hoff, R.M.; Graber, D.J.; Bercury, K.K.; Langford, G.M.; Harris, B.T. Tumor necrosis factor-alpha induces changes in mitochondrial cellular distribution in motor neurons. Neuroscience, 2007, 146, 1013-1019.
83. Liu, Y.; Hao, W.; Dawson, A.; Liu, S.; Fassbender, K. Expression of amyotrophic lateral sclerosis-linked SOD1 mutant increases the neurotoxic potential of microglia via TLR2. J. Biol. Chem., 2009, 284, 3691-3699.
84. He, B.P.; Wen, W.; Strong, M.J. Activated microglia (BV-2) facilitation of TNF-alpha-mediated motor neuron death in vitro. J. Neuroimmunol., 2002, 128, 31-38.
85. D'Ambrosi, N.; Finocchi, P.; Apolloni, S.; Cozzolino, M.; Ferri, A.; Padovano, V.; Pietrini, G.; Carri, M.T.; Volonte, C. The proinflammatory action of microglial P2 receptors is enhanced in SOD1 models for amyotrophic lateral sclerosis. J. Immunol., 2009, 183, 4648-4656.
86. Robertson, J.; Beaulieu, J.M.; Doroudchi, M.M.; Durham, H.D.; Julien, J.P.; Mushynski, W.E. Apoptotic death of neurons exhibiting peripherin aggregates is mediated by the proinflammatory cytokine tumor necrosis factor-alpha. J. Cell Biol., 2001, 155, 217-226.
87. Elliot, J.L. Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. Mol. Brain Res., 2001, 95, 172-178.
88. Hensley, K.; Floyd, R.A.; Gordon, B.; Mou, S.; Pye, Q.N.; Stewart, C.; West, M.; Williamson, K. Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93ASOD1 mouse model of amyotrophic lateral sclerosis. J. Neurochem., 2002, 82, 365-374.
89. Hensley, K.; Fedynyshyn, J.; Ferrell, S.; Floyd, R.A.; Gordon, B.; Grammas, P.; Hamdheydari, L.; Mhatre, M.; Mou, S.; Pye, Q.N.; Stewart, C.; West, M.; West, S.; Williamson, K.S. Message and protein-level elevation of tumor necrosis factor alpha (TNF alpha) and TNF alpha-modulating cytokines in spinal cords of the G93ASOD1 mouse model for amyotrophic lateral sclerosis. Neurobiol. Dis., 2003, 14, 74-80.
90. Yoshihara, T.; Ishigaki, S.; Yamamoto, M.; Liang, Y.; Niwa, J-I.; Takeuchi, H.; Doyu, M.; Sobue, G. Differential expression of inflammation- and apoptosis- related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J. Neurochem., 2002, 80, 158-167.
91. Terenghi, F.; Allaria, S.; Nobile-Orazio, E. Circulating levels of cytokines and their modulation by intravenous immunoglobulin in multifocal motor neuropathy. J. Peripheral Nervous Syst., 2006, 11, 67-71.
92. Li, M.; Ona, V.O.; Guegan, C.; Chen, M.; Jackson-Lewis, V.; Andrews, L.J.; Olszewski, A.J.; Stieg, P.E.; Lee, J.P.; Przedborski, S.; Friedlander, R.M. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science, 2000, 288, 335-339.
93. Kiaei, M.; Petri, S.; Kipiani, K.; Gardian, G.; Choi, D.K.; Chen, J.; Calingasan, N.Y.; Schafer, P.; Muller, G.W.; Stewart, C.; Hensely, K.; Beal, M.F. Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis., 2006, 26, 2467-2473.
94. Neymotin, A.; Petri, S.; Calingasan, N.Y.; Wille, E.; Schafer, P.; Stewart, C.; Hensley, K.; Beal, M.F.; Kiaei, M. Lenalidomide (Revlimid) administration at symptom onset is neuro-protective in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol., 2009, 220, 191-197.
95. Gowing, G.; Dequen, F.; Soucy, G.; Julien, J.P. Absence of tumor necrosis factor-alpha does not affect motor neuron disease caused by super-oxide dismutase 1 mutations. J. Neurosci., 2006, 26, 11397-11402.
96. Poloni, M.; Facchetti, D.; Mai, R.; Micheli, A.; Agnoletti, L.; Francolini, G.; Mora, G.; Camana, C.; Mazzini, L.; Bachetti, T. Circulating levels of tumor necrosis factor-α and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis. Neurosci. Lett., 2000, 287, 211-214.
97. Moreau, C.; Devos, D.; Brunaud-Danel, V.; Defebvre, L.; Perez, T.; Destee, A.; Tonnel, A.B.; Lassalle, P.; Just, N. Elevated IL-6 and TNF-α levels in patients with ALS: inflammation or hypoxia? Neurology, 2005, 65, 1958-1960.
98. Stommel, E.W.; Cohen, J.A.; Fadul, C.E.; Cogbill, C.H.; Graber, D.J.; Kingman, L.; Mackenzie, T.; Channon Smith, J.Y.; Harris, B.T. Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial. Amyotroph. Lateral Scler., 2009, 10, 393-404.
99. Wang, J.Y.; Peruzzi, F.; Lassak, A.; Del Valle, L.; Radhakrishnan, S.; Rappaport, J.; Khalili, K.; Amini, S.; Reiss, K. Neuroprotective effects of IGF-1 against TNFα-induced neuronal damage in HIVassociated dementia. Virology, 2003, 305, 66-76.
100. Brabers, N.A.; Nottet, H.S. Role of the pro-inflammatory cytokines TNF-alpha and IL-1beta in HIV-associated dementia. Eur. J. Clin. Invest., 2006, 36, 447-458.
101. Xing, H.Q.; Hayakawa, H.; Izumo, K.; Kubota, R.; Gelpi, E.; Budka, H.; Izumo, S. In vivo expression of proinflammatory cytokines in HIV encephalitis: an analysis of 11 autopsy cases. Neuropathology, 2009, 29, 433-442.
102. Xing, H.Q.; Hayakawa, H.; Gelpi, E.; Kubota, R.; Budka, H.; Izumo, S. Reduced expression of excitatory amino acid transporter 2 and diffuse microglial activation in the cerebral cortex in AIDS cases with or without HIV encephalitis. J. Neuropathol. Exp. Neurol., 2009, 68, 199-209.
103. Xing, H.Q.; Moritoyo, T.; Mori, K.; Sugimoto, C.; Ono, F.; Izumo, S. Expression of proinflammatory cytokines and its relationship with virus infection in the brain of macaques inoculated with macrophage-tropic simian immunodeficiency virus. Neuropathology, 2009, 29, 13-19.
104. Alirezaei, M.; Kiosses, W.B.; Flynn, C.T.; Brady, N.R.; Fox, H.S. Disruption of neuronal autophagy by infected microglia results in neurodegeneration. PLoS One, 2008, 3(8), e2906.
105. Williams, R.; Dhillon, N.K.; Hegde, S.T.; Yao, H.; Peng, F.; Callen, S.; Chebloune, Y.; Davis, R.L.; Buch, S.J. Proinflammatory cytokines and HIV-1 synergistically enhance CXCL10 expression in human astrocytes. Glia, 2009, 57, 734-743.
106. Kamat, A.; Ravi, V.; Desai, A.; Satishchandra, P.; Satish, K.S.; Kumar, M. Estimation of virological and immunological parameters in subjects from South India infected with human immunodeficiency virus type 1 clade C and correlation of findings with occurrence of neurological disease. J. Neurovirol., 2009, 15, 25-35.
107. Nolting, T.; Lindecke, A.; Koutsilieri, E.; Maschke, M.; Husstedt, I.W.; Sopper, S.; Stuve, O; Hartung, H.P.; Arendt, G.; Competence Network HIV/AIDS. Measurement of soluble inflammatory mediators in cerebrospinal fluid of human immunodeficiency viruspositive patients at distinct stages of infection by solid-phase protein array. J. Neurovirol., 2009, 15, 390-400.
108. Rostasy, K.; Monti, L.; Lipton, S.A.; Hedreen, J.C.; Gonzalez, R.G.; Navia, B.A. HIV leucoencephalopathy and TNFα expression in neurons. J. Neurol. Neurosurg. Psychiatry, 2005, 76, 960-964.
109. Okamoto, M.; Ono, M.; Baba, M. Suppression of cytokine production and neural cell death by the anti-inflammatory alkaloid cepharanthine: a potent agent against HIV-1 encephalopathy. Biochem. Pharmacol., 2001, 62, 747-753.
110. Barak, O.; Goshen, I.; Ben-Hur, T.; Weidenfeld, J.; Taylor, A.N.; Yirmiya, R. Involvement of brain cytokines in the neurobehavioral disturbances induced by HIV-1 glycoprotein 120. Brain Res., 2002, 933, 98-108.
111. Ghoshal, A.; Das, S.; Ghosh, S.; Mishra, M.K.; Sharma, V.; Koli, P.; Sen, E.; Basu, A. Proinflammatory mediators released by activated microglia induces neuronal death in Japanese encephalitis. Glia, 2007, 55, 483-496.
112. Chen, C.J.; Ou, Y.C.; Lin, S.Y.; Raung, S.L.; Liao, S.L.; Lai, C.Y.; Chen, S.Y.; Chen, J.H. Glial activation involvement in neuronal death by Japanese encephalitis virus infection. J. Gen. Virol., 2010, 91, 1028-1037.
113. Tsao, C.H.; Su, H.L.; Lin, Y.L.; Yu, H.P.; Kuo, S.M.; Shen, C.I.; Chen, C.W.; Liao, C.L. Japanese encephalitis virus infection activates caspase-8 and -9 in a FADD-independent and mitochondrion-dependent manner. J. Gen. Virol., 2008, 89, 1930-1941.
114. Swarup, V.; Das, S.; Ghosh, S.; Basu, A. Tumor necrosis factor receptor-1-induced neuronal death by TRADD contributes to the pathogenesis of Japanese encephalitis. J. Neurochem., 2007, 103, 771-783.
115. Swarup, V.; Ghosh, J.; Das, S.; Basu, A. Tumor necrosis factor receptor-associated death domain mediated neuronal death contributes to the glial activation and subsequent neuroinflammation in Japanese encephalitis. Neurochem. Int., 2008, 52, 1310-1321.
116. Hosoya, M.; Kawasaki, Y.; Katayose, M.; Sakuma, H.; Watanabe, M.; Igarashi, E.; Aoyama, M.; Nunoi, H.; Suzuki, H. Prognostic predictive values of serum cytochrome c, cytokines, and other laboratory measurements in acute encephalopathy with multiple organ failure. Arch. Dis. Child., 2006, 91, 469-472.
117. Kalita, J.; Srivastava, R.; Mishra, M.K.; Basu, A.; Misra, U.K. Cytokines and chemokines in viral encephalitis: a clinicoradiological correlation. Neurosci. Lett., 2010, 473, 48-51.
118. Kawada, J-I.; Kimura, H.; Ito, Y.; Hara, S.; Iriyama, M.; Yoshikawa, T.; Morishima, T. Systemic cytokine responses in patients with influenza-associated encephalopathy. J. Infect. Dis., 2003, 188, 690-698.
119. Nunoi, H.; Mercado, M.R.; Mizukami, T.; Okajima, K.; Morishima, T.; Sakata, H.; Nakayama, S.; Mori, S.; Hayashi, M.; Mori, H.; Kagimoto, S.; Kanegasaki, S.; Watanabe, K.; Adachi, N.; Endo, F. Apoptosis under hypercytokinemia is a possible pathogenesis in influenza-associated encephalopathy. Pediatr. Int., 2005, 47, 175-179.
120. Hosoya, M.; Nunoi, H.; Aoyama, M.; Kawasaki, Y.; Suzuki, H. Cytochrome c and tumor necrosis factor-α values in serum and cerebrospinal fluid of patients with influenza-associated encephalopathy. Ped. Infect. Dis. J., 2005, 24, 467-470.
121. Babu, G.N.; Kalita, J.; Misra, U.K. Inflammatory markers in the patients of Japanese encephalitis. Neurol. Res., 2006, 28, 190-192.
122. Garner, J.; Brett, S.J. Mechanisms of injury by explosive devices. Anesthesiol. Clin., 2007, 25, 147-160.
123. Moppett, I.K. Traumatic brain injury: assessment, resuscitation and early management. Br. J. Anaesth., 2007, 99, 18-31.
124. Raghupathi, R. Cell death mechanisms following traumatic brain injury. Brain Pathol., 2004, 14, 215-222.
125. Lu, J.; Goh, S.J.; Tng, P.Y.; Deng, Y.Y.; Ling, E.A.; Moochhala, S. Systemic inflammatory response following acute traumatic brain injury. Front. Biosci., 2009, 14, 3795-3813.
126. Yang, J.; You, Z.; Kim, H.H.; Hwang, S.K.; Khuman, J.; Guo, S.; Lo, E.H.; Whalen, M.J. Genetic analysis of the role of tumor necrosis factor receptors in functional outcome after traumatic brain injury in mice. J. Neurotrauma, 2010, 27, 1037-1046.
127. Shohami, E.; Gallily, R.; Mechoulam, R.; Bass, R.; Ben-Hur, T. Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-α inhibitor and an effective neuroprotectant. J. Neuroimmunol., 1997, 72, 169-177.
128. Israelsson, C.; Wang, Y.; Kylberg, A.; Pick, C.G.; Hoffer, B.J.; Ebendal, T. Closed head injury in a mouse model results in molecular changes indicating inflammatory responses. J. Neurotrauma, 2009, 26, 1307-1314.
129. Taupin, V.; Toulmond, S.; Serrano, A.; Benavides, J.; Zavala, F. Increase in IL-6, IL-1 and TNF levels in rat brain following traumatic lesion: influence of pre- and post-traumatic treatment with Ro5 4864, a peripheral-type (p site) benzodiazepine ligand. J. Neuroimmunol., 1993, 42, 177-185.
130. Shohami, E.; Novikov, M.; Bass, R.; Yamin, A.; Gallily, R. Closed head injury triggers early production of TNFα and IL-6 by brain tissue. J. Cereb. Blood Flow Metab., 1994, 14, 615-619.
131. Knoblach, S.M.; Fan, L.; Faden, A.I. Early neuronal expression of tumor necrosis factor-α after experimental brain injury contributes to neurological impairment. J. Neuroimmunol., 1999, 95, 115-125.
132. Winter, C.D.; Iannotti, F.; Pringle, A.K.; Trikkas, C.; Clough, G.F.; Church, M.K. A microdialysis method for the recovery of IL-1β, IL-6 and nerve growth factor from human brain in vivo. J. Neurosci. Methods, 2002, 119, 45-50.
133. Woodroofe, M.N.; Sarna, G.S.; Wadhwa, M.; Hayes, G.M.; Loughlin, A.J.; Tinker, A.; Cuzner, M.L. Detection of interleukin-1 and interleukin-6 in adult rat brain, following mechanical injury, by in vivo microdialysis: evidence of a role for microglia in cytokine production. J. Neuroimmunol., 1991, 33, 227-236.
134. Scherbel, U.; Raghupathi, R.; Nakamura, M.; Saatman, K.E.; Trojanowski, J.Q.; Neugebauer, E.; Marino, M.W.; McIntosh, T.K. Differential acute and chronic responses of tumor necrosis factordeficient mice to experimental brain injury. Proc. Natl. Acad. Sci. USA, 1999, 96, 8721-8726.
135. Stahel, P.F.; Shohami, E.; Younis, F.M.; Kariya, K.; Otto, V.I.; Lenzlinger, P.M.; Grosjean, M.B.; Eugster, H.P.; Trentz, O.; Kossmann, T.; Morganti-Kossmann, M.C. Experimental closed head injury: analysis of neurological outcome, blood-brain barrier dysfunction, intracranial neutrophil infiltration, and neuronal cell death in mice deficient in genes for pro-inflammatory cytokines. J. Cereb. Blood Flow Metab., 2000, 20, 369-380.
136. Sullivan, P.G.; Bruce-Keller, A.J.; Rabchevsky, A.G.; Christakos, S.; Clair, D.K.; Mattson, M.P.; Scheff, S.W. Exacerbation of damage and altered NF-κB activation in mice lacking tumor necrosis factor receptors after traumatic brain injury. J. Neurosci., 1999, 19, 6248-6256.
137. Rosenberg, G.A.; Estrada, E.Y.; Dencoff, J.E.; Stetler-Stevenson, W.G. Tumor necrosis factor-alpha-induced gelatinase B causes delayed opening of the blood-brain barrier: an expanded therapeutic window. Brain Res., 1995, 703, 151-155.
138. Ye, Z.C.; Sontheimer, H. Cytokine modulation of glial glutamate uptake: a possible involvement of nitric oxide. Neuroreport, 1996, 7, 2181-2185.
139. Barone, F.C.; Arvin, B.; White, R.F.; Miller, A.; Webb, C.L.; Willete, R.N.; Lysko, P.G.; Feuerstein, G.Z. Tumor necrosis factoralpha: a mediator of focal ischemic brain injury. Stroke, 1998, 28, 1233-1244.
140. Delannoy, I.; Lekeux, P.; Miossec, P. Cytokine and anti-cytokine strategies in inflammatory reaction modulation. Vet. Res., 1993, 24, 449-467.
141. Park, K.M.; Bowers, W.J. Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Cell Signal., 2010, 22, 977-983.
142. Ikonomidou, C.; Stefovska, V.; Turski, L. Neuronal death enhanced by N-methyl-D-aspartate antagonists. Proc. Natl. Acad. Sci. USA, 2000, 97, 12885-12890.
143. Chadwick, W.; Magnus, T.; Martin, B.; Keselman, A.; Mattson, M.P.; Maudsley, S. Targeting TNF-α receptors for neurotherapeutics. Trends Neurosci., 2008, 311, 504-511.
144. Shiraki, M.; Terakura, Y.; Iwasa, J.; Shimizu, M.; Miwa, Y.; Murakami, N.; Nagaki, M.; Moriwaki, H. Elevated serum tumor necrosis factor-alpha and soluble tumor necrosis factor receptors correlate with aberrant energy metabolism in liver cirrhosis. Nutrition, 2010, 26, 269-275.
145. Clark, I.A. How TNF was recognized as a key mechanism of disease. Cytokine Growth Factor Rev., 2007, 18, 335-343.
146. Idriss, H.T.; Naismith, J.H. TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc. Res. Tech., 2000, 50, 184-195.
147. MacEwan, D.J. TNF receptor subtype signaling: differences and cellular consequences. Cell Signal., 2002, 14, 414-434.
148. Lieberman, A.P.; Pitha, P.M.; Shin, H.S.; Shin, M.L. Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proc. Natl. Acad. Sci. USA, 1989, 86, 6348-6352.
149. Morganti-Kossman, M.C.; Lenzlinger, P.M.; Hans, V.; Stahel, P.; Csuka, E.; Ammann, E.; Stocker, R.; Trentz, O.; Kossmann, T. Production of cytokines following brain injury: beneficial and deleterious for the damaged tissue. Mol. Psychiatry, 1997, 2, 133-136.
150. 2+ accumulation. Proc. Natl. Acad. Sci. USA, 1995, 92, 9328-9332.
151. Marchetti, L.; Klein, M.; Schlett, K.; Pfizenmaier, K.; Eisel, U.L. Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-Daspartate receptor activation: essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappa B pathway. J. Biol. Chem., 2004, 279, 32869-32881.
152. Chen, G.; Goeddel, D.V. TNF-R1 signaling: a beautiful pathway. Science, 2002, 296, 1634-1635.
153. Grell, M. Tumor necrosis factor (TNF) receptors in cellular signaling of soluble and membrane-expressed TNF. J. Inflammation, 1995, 47, 8-17.
154. Grell, M.; Wajant, H.; Zimmermann, G.; Scheurich, P. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc. Natl. Acad. Sci. USA, 1998, 95, 570-575.
155. Tartaglia, L.A.; Ayres, T.M.; Wong, G.H.; Goeddel, D.V. A novel domain within the 55 kd TNF receptor signals cell death. Cell, 1993, 74, 845-853.
156. Ware, C.F.; VanArsdale, S.; VanArsdale, T.L. Apoptosis mediated by the TNF-related cytokine and receptor families. J. Cell. Biochem., 1996, 60, 47-55.
157. Lorz, C.; Mehmet, H. The role of death receptors in neural injury. Front. Biosci., 2009, 14, 583-595.
158. De Vos, K.; Goossens, V.; Boone, E.; Vercammen, D.; Vancompernolle, K.; Vandenabeele, P.; Haegeman, G.; Fiers, W.; Grooten, J. The 55-kDa tumor necrosis factor receptor induces clustering of mitochondria through its membrane-proximal region. J. Biol. Chem., 1998, 273, 9673-9680.
159. De Vos, K.; Severin, F.; Van Herreweghe, F.; Vancompernolle, K.; Goossens, V.; Hyman, A.; Grooten, J. Tumor necrosis factor induces hyperphosphorylation of kinesin light chain and inhibits kinesin-mediated transport of mitochondria. J. Cell. Biol., 2000, 149, 1207-1214.
160. Reale, M.; Greig, N.H.; Kamal, M.A. Peripheral chemo-cytokine profiles in Alzheimer's and Parkinson's diseases. Mini Rev. Med. Chem., 2009, 9, 1229-1241.
161. Moreira, A.L.; Sampaio, E.P.; Zmuidzinas, A.; Frindt, P.; Smith, K.; Kaplan, G. Thalidomide exerts its inhibitor action on tumor necrosis factor alpha by enhancing mRNA degradation. J. Exp. Med., 1993, 177, 1675-1680.
162. Aragon-Ching, J.B.; Li, H.; Gardner, E.R.; Figg, W.D. Thalidomide analogues as anticancer drugs. Recent Pat. Anticancer Drug Discov., 2007, 2, 167-174.
163. Knight, R. IMiDs: a novel class of immunomodulators. Semin. Oncol., 2005, 32(5), S24-S30.
164. Melchert, M.; List, A. The thalidomide saga. Int. J. Biochem. Cell Biol., 2007, 39, 1489-1499.
165. Wines, N.Y.; Cooper, A.J.; Wines, M.P. Thalidomide in dermatology. Australas. J. Dermatol., 2002, 43, 229-240.
166. Randall, T. Thalidomide has 37-year history. JAMA, 1990, 263, 1474.
167. Bellamy, W.; Richter, L.; Sirjani, D.; Roxas, C.; Glinsmann-Gibson, B.; Frutiger, Y.; Grogan, T.M.; List, A.F. Vascular endothelial growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood, 2001, 97, 1427-1434.
168. Gupta, D.; Treon, S.P.; Shima, Y.; Hideshima, T.; Podar, K.; Tai, Y.T.; Lin, B.; Lentzsch, S.; Davies, F.E.; Chauhan, D.; Schlossman, R.L.; Richardson, P.; Ralph, P.; Wu, L.; Pavandi, F.; Muller, G.; Stirling, D.I.; Anderson, K.C. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia, 2001, 15, 1950-1961.
169. Zhu, X.; Giordano, T.; Yu, Q.S.; Holloway, H.W.; Perry, T.A.; Lahiri, D.K.; Brossi, A.; Greig, N.H. Thiothalidomides: novel isosteric analogues of thalidomide with enhanced TNF-alpha inhibitory activity. J. Med. Chem., 2003, 46, 5222-5229.
170. D'Amato, R.; Loughnan, M.S.; Flynn, E.; Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA, 1994, 91, 4082-4085.
171. Hashimoto, Y. Thalidomide as a multi-template for development of biologically active compounds. Arch. Pharm. Chem. Life Sci., 2008, 341, 536-547.
172. Greig, N.H.; Giordano, T.; Zhu, X.; Yu, Q.S.; Perry, T.; Holloway, H.W.; Brossi, A.; Rogers, J.T.; Sambamurti, K.; Lahiri, D.K. Thalidomide-based TNF-α inhibitors for neurodegenerative disease. Acta Neurobiol. Exp., 2004, 64, 1-9.
173. Luo, W.; Yu, Q.S.; Tweedie, D.; Deschamps, J.; Parrish, D.; Holloway, H.W.; Li, Y.; Brossi, A.; Greig, N.H. Syntheses of aromatic substituted 6'-thiothalidomides. Synthesis, 2008, 21, 3415-3422.
174. Tweedie, D.; Luo, W.; Short, R.G.; Brossi, A.; Holloway, H.W.; Li, Y.; Yu, Q.S.; Greig, N.H. A cellular model of inflammation for identifying TNF-alpha synthesis inhibitors. J. Neurosci. Methods, 2009, 183, 182-187.
175. Dowlati, Y.; Herrmann, N.; Swardfager, W.; Liu, H.; Sham, L.; Reim, E.K.; Lanctôt, K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry, 2010, 67, 446-457.
176. Schroeter, M.L.; Abdul-Khaliq, H.; Krebs, M.; Diefenbacher, A.; Blasig, I.E. Serum markers support disease-specific glial pathology in major depression. J. Affect. Disord., 2008, 111, 271-280.
177. Ekdahl, C.T.; Claasen, H.H.; Bonde, S.; Kokaia, Z.; Lindvall, O. Inflammation is detrimental for neurogenesis in adult brain. Proc. Natl. Acad. Sci. USA, 2003, 100, 13632-13637.
178. Iosif, R.E.; Ekdahl, C.T.; Ahlenius, H.; Pronk, C.J.; Bonde, S.; Kokaia, Z.; Jacobsen, S.E.; Lindvall, O. Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis. J. Neurosci., 2006, 26, 9703-9712.
179. Bilbo, S.D.; Schwarz, J.M. Early-life programming of later-life brain and behavior: a critical role for the immune system. Front. Behav. Neurosci., 2009, 3, 14.
180. Keohane, A.; Ryan, S.; Maloney, E.; Sullivan, A.M.; Nolan, Y.M. Tumour necrosis factor-alpha impairs neuronal differentiation but not proliferation of hippocampal neural precursor cells: role of Hes1. Mol. Cell. Neurosci., 2010, 43, 127-135.
181. Liu, J.L.; Tian, D.S.; Li, Z.W.; Qu, W.S.; Zhan, Y.; Xie, M.J.; Yu, Z.Y.; Wang, W.; Wu, G. Tamoxifen alleviates irradiation-induced brain injury by attenuating microglial inflammatory response in vitro and in vivo. Brain Res., 2010, 1316, 101-111.
182. Iosif, R.E.; Ahlenius, H.; Ekdahl, C.T.; Darsalia, V.; Thored, P.; Jovinge, S.; Kokaia, Z.; Lindvall, O. Suppression of stroke-induced progenitor proliferation in adult subventricular zone by tumor necrosis factor receptor 1. J. Cereb. Blood Flow Metab., 2008, 28, 1574-1587.
183. Dziegielewska, K.M.; Møller, J.E.; Potter, A.M.; Ek, J.; Lane, M.A.; Saunders, N.R. Acute-phase cytokines IL-1beta and TNF alpha in brain development. Cell Tissue Res., 2000, 299, 335-345.
184. Benasciutti, E.; Pagès, G.; Kenzior, O.; Folk, W.; Blasi, F.; Crippa, M.P. MAPK and JNK transduction pathways can phosphorylate Sp1 to activate the uPA minimal promoter element and endogenous gene transcription. Blood, 2004, 104, 256-262.
185. Schneider-Brachert, W.; Tchikov, V.; Neumeyer, J.; Jakob, M.; Winoto-Morbach, S.; Held-Feindt, J.; Heinrich, M.; Merkel, O.; Ehrenschwender, M.; Adam, D.; Mentlein, R.; Kabelitz, D.; Schütze, S. Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity, 2004, 21, 415-428.